You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

131-I apamistamab

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

B-ALL, DLBCL, B ALL Trial in New York (131-I Apamistamab, CAR T-cell)

Recruiting
  • B-ALL
  • +10 more
  • 131-I Apamistamab
  • CAR T-cell
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 7, 2022

Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Edmonton ([131]I-IAZA)

Withdrawn
  • Locally Advanced Solid Tumors
  • Metastatic Solid Tumors
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Jul 7, 2022

Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia Trial in Worldwide (Iopofosine I 131 single dose,

Recruiting
  • Waldenstrom Macroglobulinemia
  • +8 more
  • Iopofosine I 131 single dose
  • +2 more
  • Redlands, California
  • +42 more
Dec 30, 2022

Neuroblastoma, Childhood Metastatic Pheochromocytoma Trial in Philadelphia (131 I-Metaiodobenzylguanidine (131 I-MIBG), 131

Available
  • Neuroblastoma
  • Childhood Metastatic Pheochromocytoma
  • 131 I-Metaiodobenzylguanidine (131 I-MIBG)
  • 131 I-MIBG
  • Philadelphia, Pennsylvania
    The Children's Hospital of Philadelphia
Jul 11, 2022

Thyroid Cancer, Thyroid Carcinoma, Metastatic Thyroid Cancer Trial in Boston (Selpercatinib, Sodium Iodine I-131, rhTSH)

Not yet recruiting
  • Thyroid Cancer
  • +5 more
  • Boston, Massachusetts
    Massachusetts General Hospital
Dec 20, 2022

Thyroid Cancer Trial in Bialystok (metformin, Radioactive iodine (I-131))

Not yet recruiting
  • Thyroid Cancer
  • Bialystok, Poland
    Department of Endocrinology, Diabetology and Internal Medicine,
Jul 26, 2022

Renal Tracer Elimination in Thyroid Cancer Patients Treated With

Completed
  • Thyroid Carcinoma
    • Jena, Thüringen, Germany
      University Hospital Jena
    Dec 15, 2022

    Thyroid Cancer Trial run by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (drug, radiation,

    Recruiting
    • Thyroid Cancer
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 28, 2023

    Thyroid Cancer Trial in New York (131 I-iodine (131-I), 124 I-iodine (124-I))

    Active, not recruiting
    • Thyroid Cancer
    • 131 I-iodine (131-I), 124 I-iodine (124-I)
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Apr 1, 2022

    Kidney Cancer Trial in New York (Iodine-131 radiolabeled chimeric mAb G250 (131I-cG250))

    Completed
    Has Results
    • Kidney Cancer
    • Iodine-131 radiolabeled chimeric monoclonal antibody G250 (131I-cG250)
    • New York, New York
      Memorial Sloan-Kettering Cancer Center
    Oct 3, 2022

    HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

    Not yet recruiting
    • HER2-positive Breast Cancer
    • 68Ga/131I-SGMIB-5F7
    • Shanghai, China
      Huashan Hospital
    Aug 1, 2023

    Multiple Myeloma Trial in Ann Arbor (Iodine I 131 Tositumomab)

    Active, not recruiting
    Has Results
    • Multiple Myeloma
    • Iodine I 131 Tositumomab
    • Ann Arbor, Michigan
      University of Michigan
    Mar 16, 2022

    Follicular Lymphoma Trial in Chicago (Bortezomib and Tositumomab I-131)

    Terminated
    Has Results
    • Follicular Lymphoma
    • Bortezomib and Tositumomab I-131
    • Chicago, Illinois
      Rush University Medical Center
    Oct 6, 2021

    High-Grade Glioma Trial in New York, Houston, Madison (CLR 131)

    Not yet recruiting
    • High-Grade Glioma
    • CLR 131
    • New York, New York
    • +2 more
    Nov 3, 2022

    Differentiated Thyroid Cancer Trial in Leiden (rhTSH-stimulated I-124 dosimetry, Intra-therapeutic I-131 dosimetry)

    Recruiting
    • Differentiated Thyroid Cancer
    • rhTSH-stimulated I-124 dosimetry
    • Intra-therapeutic I-131 dosimetry
    • Leiden, Zuid-Holland, Netherlands
      Leiden University Medical Center
    Apr 8, 2022

    Melanoma Trial in Clermont-Ferrand ([131I]ICF01012 (therapeutic dose level 1), [131I]ICF01012 (therapeutic dose level 2),

    Recruiting
    • Melanoma
    • [131I]ICF01012 (therapeutic dose level 1)
    • +3 more
    • Clermont-Ferrand, France
    • +1 more
    Jan 27, 2022

    Thyroid Nodule, Toxic or With Hyperthyroidism, Autonomous Thyroid Function, Thyroid Nodule; Hyperthyroidism Trial in Arnhem,

    Recruiting
    • Thyroid Nodule, Toxic or With Hyperthyroidism
    • +5 more
    • Radiofrequency ablation
    • Radioactive iodine
    • Arnhem, Gelderland, Netherlands
    • +1 more
    Dec 2, 2021

    Relapsed Neuroblastoma, Metastatic Pheochromocytoma Trial in Dallas (131 I-Metaiodobenzylguanidine, Potassium Iodide, G-csf)

    No longer available
    • Relapsed Neuroblastoma
    • Metastatic Pheochromocytoma
    • 131 I-Metaiodobenzylguanidine
    • +2 more
    • Dallas, Texas
      The University of Texas Southwestern Medical Center
    Apr 13, 2022

    Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)

    Active, not recruiting
    • Brain and Central Nervous System Tumors
    • +9 more
    • DNA analysis
    • +4 more
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Oct 28, 2021

    Neoplastic Disease, Glioblastoma, Glioblastoma Multiforme Trial (131I-IPA)

    Not yet recruiting
    • Neoplastic Disease
    • +2 more
    • (no location specified)
    Jul 6, 2022

    DIPG Trial (131I-Omburtamab, Convention Enhanced Delivery)

    Not yet recruiting
    • DIPG
    • (no location specified)
    Feb 7, 2022

    CNS/Leptomeningeal Tumors Trial in New York (131I-omburtamab)

    Available
    • Central Nervous System/Leptomeningeal Neoplasms
    • New York, New York
      Memorial Sloan Kettering Cancer Center
    Jul 15, 2022

    Neuroblastoma Trial in United States (131I-MIBG, Dinutuximab, Vorinostat)

    Recruiting
    • Neuroblastoma
    • 131I-MIBG
    • +4 more
    • Los Angeles, California
    • +11 more
    Jan 30, 2023

    Disseminated Neuroblastoma, Ganglioneuroblastoma, Localized Resectable Neuroblastoma Trial in United States (drug, radiation,

    Active, not recruiting
    Has Results
    • Disseminated Neuroblastoma
    • +5 more
    • Birmingham, Alabama
    • +22 more
    Mar 3, 2022

    Neuroblastoma Trial in Canada, United States (131I-MIBG, Vincristine, Irinotecan)

    Completed
    Has Results
    • Neuroblastoma
    • 131I-MIBG
    • +3 more
    • Los Angeles, California
    • +13 more
    May 16, 2022